HOUSTON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has engaged with Southern Star Research to provide clinical research organization (CRO) services for FibroBiologics in Australia. Initial CRO services will include prepara ...